Michael Povey

gsk

H指数:13

被引数:620

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunogenicity and safety of an investigational varicella zoster vaccine in toddlers aged 12–15 months: results of a phase II, controlled, randomized trial

12～15月龄幼儿中一种试验性水痘带状疱疹疫苗的免疫原性和安全性：一项II期、对照、随机试验的结果

Vaccine

IF3.5

2026-03-120

OAAI

Clinical trials show similar safety outcomes including febrile convulsion rates for GSK's and Merck's measles-mumps-rubella (MMR) vaccines

临床试验显示，葛兰素史克公司和默克公司的麻疹-腮腺炎-风疹（MMR）疫苗在安全性指标方面表现相似，其中包括发热性惊厥的发生率。

HUMAN VACCINES & IMMUNOTHERAPEUTICS

IF3.5

2023-03-292

OAAI

No Consistent Evidence of Decreased Exposure to Varicella-Zoster Virus Among Older Adults in Countries with Universal Varicella Vaccination

在普遍接种水痘疫苗的国家，没有一致的证据表明老年人接触水痘病毒减少

JOURNAL OF INFECTIOUS DISEASES

IF4.5

2021-10-056

OAAI

A randomized trial assessing the efficacy, immunogenicity, and safety of vaccination with live attenuated varicella zoster virus-containing vaccines: ten-year follow-up in Russian children

HUMAN VACCINES & IMMUNOTHERAPEUTICS

IF3.5

2021-08-265

OAAI

Clinically- versus serologically-identified varicella: A hidden infection burden. A ten-year follow-up from a randomized study in varicella-endemic countries

HUMAN VACCINES & IMMUNOTHERAPEUTICS

IF3.5

2021-06-284

OAAI

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)

EUROPEAN PSYCHIATRY

IF6.7

2020-04-16142

PREAI

Assessment of Mumps Virus-Specific Antibodies: Comparison of Plaque Reduction Neutralization Test and Enzyme-Linked Immunosorbent Assay Estimates

JOURNAL OF INFECTIOUS DISEASES

IF4.5

2019-07-119

OAAI

Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial

LANCET INFECTIOUS DISEASES

IF31

2019-03-0135

PREAI

Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study

对7岁或以上的健康参与者进行第二剂麻疹-腮腺炎-风疹疫苗的免疫原性和安全性: 一项III期随机研究

HUMAN VACCINES & IMMUNOTHERAPEUTICS

IF3.5

2018-06-1410

OAAI

Two-year antibody persistence in children vaccinated at 12-15months with a measles-mumps-rubella virus vaccine without human serum albumin

在12-15个月接种不含人血清白蛋白的麻疹-腮腺炎-风疹病毒疫苗的儿童中，两年的抗体持久性

HUMAN VACCINES & IMMUNOTHERAPEUTICS

IF3.5

2017-05-089

OAAI

Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore A phase II, randomized, double-blind trial

在台湾和新加坡的健康儿童中使用新的麻疹和风疹工作种子的麻疹-腮腺炎-风疹-水痘联合疫苗的免疫原性和安全性

HUMAN VACCINES & IMMUNOTHERAPEUTICS

IF3.5

2014-11-037

OAAI

Risperidone long-acting injection in the treatment of recently versus longer diagnosed patients with schizophrenia

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2008-08-010

PREAI

Assessing remission in schizophrenia patients treated with long-acting risperidone in clinical practice

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2008-08-010

PREAI

Improvement in personal and social functioning in schizophrenia patients treated with risperidone long acting injection): 6-month results from E-star

VALUE IN HEALTH

IF6

2008-05-010

OAAI

Treatment outcomes of risperidone long acting injection (RLAI) in schizophrenia: 18-month results from the electronic schizophrenia treatment adherence registry (E-STAR) in Czech Republic and Slovakia

VALUE IN HEALTH

IF6

2008-05-010

OAAI

Clinical and functional improvements in patients with schizophrenia treated with risperidone long acting injection: Interim results from observational studies conducted in Australia, Belgium and the United States

VALUE IN HEALTH

IF6

2008-05-010

OAAI

Impact of risperidone long-acting injection versus oral antipsychotic treatments on hospitalization in schizophrenia

VALUE IN HEALTH

IF6

2008-05-010

OAAI

Remission in patients with schizophrenia treated with risperidone long-acting injection:: Results from the e-STAR project in Czech Republic and Slovakia

EUROPEAN PSYCHIATRY

IF6.7

2008-04-010

PREAI

Clinical and functional improvements with risperidone long-acting injection treatment: 6-month results from the electronic schizophrenia treatment adherence registry in Sweden

EUROPEAN PSYCHIATRY

IF6.7

2008-04-010

PREAI

Patient and physician satisfaction with risperidone long-acting injection: 18-month interim results from the electronic schizophrenia treatment adherence registry in Belgium

EUROPEAN PSYCHIATRY

IF6.7

2008-04-010

PREAI

Michael Povey

个人简介

教育背景

工作经历

荣誉奖项

研究方向